LifeMD (NasdaqGM:LFMD) - Share price, News & Analysis

LFMD fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	2/6
Past Performance	0/6
Financial Health	4/6
Dividends	0/6

LFMD Stock Overview

Rewards

Revenue is forecast to grow 26.13% per year

Risk Analysis

Has less than 1 year of cash runway

Currently unprofitable and not forecast to become profitable over the next 3 years

Shareholders have been diluted in the past year

Does not have a meaningful market cap ($66M)

LifeMD Competitors

Hims & Hers Health

NYSE:HIMS

US$704.7m

Price History & Performance

Summary of all time highs, changes and price drops for LifeMD
Historical stock prices
Current Share Price	US$2.13
52 Week High	US$16.28
52 Week Low	US$1.85
Beta	1.03
1 Month Change	-23.93%
3 Month Change	-38.97%
1 Year Change	-81.70%
3 Year Change	184.00%
5 Year Change	21.68%
Change since IPO	-19.62%

Shareholder Returns

	LFMD	US Personal Products	US Market
7D	0.9%	-4.8%	-4.0%
1Y	-81.7%	-29.9%	-13.2%

Return vs Industry: LFMD underperformed the US Personal Products industry which returned -27.9% over the past year.

Return vs Market: LFMD underperformed the US Market which returned -12.3% over the past year.

Price Volatility

Is LFMD's price volatile compared to industry and market?
LFMD volatility
LFMD Average Weekly Movement	10.6%
Personal Products Industry Average Movement	10.4%
Market Average Movement	7.8%
10% most volatile stocks in US Market	16.8%
10% least volatile stocks in US Market	2.9%

Stable Share Price: LFMD is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 11% a week.

Volatility Over Time: LFMD's weekly volatility (11%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1994	197	Justin Schreiber	https://www.lifemd.com

LifeMD, Inc. operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for care across various indications, including concierge care, men’s sexual health, dermatology, and others in the United States. The company provides ShapiroMD, a telehealth platform brand that offers access to virtual medical treatment, prescription medications, patented-doctor formulated OTC products, and an FDA approved medical device for male and female hair loss, and female specific topical compounded medications for hair loss; RexMD, a men’s telehealth brand that offers virtual medical treatment from licensed providers for a variety of men’s health needs; LifeMD Primary Care, a personalized subscription-based virtual primary care platform that provides patients with primary care, urgent care, and chronic care needs, as well as offers a mobile first platform that incorporates virtual consultations and treatment, prescription medications, diagnostics, and imaging; Cleared, a telehealth brand that provides personalized treatments for allergy, asthma, and immunology; and Nava MD, a female-oriented tele-dermatology and skincare brand that offers virtual medical treatment from dermatologists and other providers.

LifeMD Fundamentals Summary

How do LifeMD's earnings and revenue compare to its market cap?
LFMD fundamental statistics
Market Cap	US$65.60m
Earnings (TTM)	-US$64.24m
Revenue (TTM)	US$103.72m

0.6x

P/S Ratio

-1.0x

P/E Ratio

Is LFMD overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
LFMD income statement (TTM)
Revenue	US$103.72m
Cost of Revenue	US$20.03m
Gross Profit	US$83.69m
Other Expenses	US$147.93m
Earnings	-US$64.24m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)	-2.09
Gross Margin	80.69%
Net Profit Margin	-61.94%
Debt/Equity Ratio	0.4%

How did LFMD perform over the long term?

See historical performance and comparison

Valuation

Is LifeMD undervalued compared to its fair value and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PEG Ratio
PB vs Industry

4.98x

Price to Book (PB) ratio

Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate LFMD's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate LFMD's fair value for valuation analysis.

Price To Earnings Ratio

PE vs Industry: LFMD is unprofitable, so we can't compare its Price-To-Earnings Ratio to the US Personal Products industry average.

PE vs Market: LFMD is unprofitable, so we can't compare its Price-To-Earnings Ratio to the US market.

Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate LFMD's PEG Ratio to determine if it is good value.

Price to Book Ratio

PB vs Industry: LFMD is overvalued based on its Price-To-Book Ratio (5x) compared to the US Personal Products industry average (2x).

Future Growth

How is LifeMD forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

Future Growth Score

2/6

Future Growth Score 2/6

Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE

78.2%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings vs Savings Rate: LFMD is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: LFMD is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: LFMD is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: LFMD's revenue (26.1% per year) is forecast to grow faster than the US market (7.8% per year).

High Growth Revenue: LFMD's revenue (26.1% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if LFMD's Return on Equity is forecast to be high in 3 years time

Past Performance

How has LifeMD performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE

-71.5%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: LFMD is currently unprofitable.

Growing Profit Margin: LFMD is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: LFMD is unprofitable, and losses have increased over the past 5 years at a rate of 71.5% per year.

Accelerating Growth: Unable to compare LFMD's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: LFMD is unprofitable, making it difficult to compare its past year earnings growth to the Personal Products industry (34.9%).

Return on Equity

High ROE: LFMD has a negative Return on Equity (-383.53%), as it is currently unprofitable.

Financial Health

How is LifeMD's financial position?

Financial Health Score

4/6

Financial Health Score 4/6

Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: LFMD's short term assets ($29.6M) exceed its short term liabilities ($25.6M).

Long Term Liabilities: LFMD's short term assets ($29.6M) exceed its long term liabilities ($8.3M).

Debt to Equity History and Analysis

Debt Level: LFMD has more cash than its total debt.

Reducing Debt: LFMD had negative shareholder equity 5 years ago, but is now positive and has therefore improved.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: LFMD has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: LFMD has less than a year of cash runway if free cash flow continues to reduce at historical rates of 70.9% each year

Dividend

What is LifeMD current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate LFMD's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate LFMD's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if LFMD's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if LFMD's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as LFMD has not reported any payouts.

Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

1.3yrs

Average management tenure

CEO

Justin Schreiber (38 yo)

4.25yrs

Tenure

US$180,000

Compensation

Mr. Justin Schreiber served as an Independent Director at Quantum Computing Inc until September 22, 2021. Mr. Schreiber has been Chairman of the Board at LifeMD, Inc. (formerly known as Conversion Labs, In...

CEO Compensation Analysis

Compensation vs Market: Justin's total compensation ($USD180.00K) is below average for companies of similar size in the US market ($USD770.27K).

Compensation vs Earnings: Justin's compensation has been consistent with company performance over the past year.

Leadership Team

Experienced Management: LFMD's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.

Board Members

Experienced Board: LFMD's board of directors are considered experienced (3.5 years average tenure).

Ownership

Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: LFMD insiders have bought more shares than they have sold in the past 3 months.

Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 17.8%.

Data	Last Updated (UTC time)
Company Analysis	2022/05/24 00:00
End of Day Share Price	2022/05/24 00:00
Earnings	2022/03/31
Annual Earnings	2021/12/31